New and emerging drug molecules against obesity.
Kānchipuram, India. In J Cardiovasc Pharmacol Ther, 2014
Tesofensine is a triple monoamine re-uptake inhibitor, velneperit acts as a neuropeptide Y5 receptor antagonist and beloranib is a methionine amino peptidase 2 inhibitor.
Bethesda, United States. In Unknown Journal, 2012
The Y2 and Y4 receptor subtypes are thought to inhibit appetite, whereas the Y1 and Y5 receptor subtypes are responsible for stimulation of appetite.
Treating obesity: does antagonism of NPY fit the bill?
Cambridge, United Kingdom. In Cell Metab, 2006
In this issue of Cell Metabolism, Erondu et al., (2006) identify a selective neuropeptide Y5 receptor antagonist that, as predicted from rodent studies, results in weight loss when administered to overweight and obese human subjects.